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Objective: To report our experiences in changing from intravitreal bevacizumab to ranibizumab 
in age-related macular degeneration (AMD).
Design: Retrospective case series.
Participants and methods: We retrospectively reviewed the records of 34 patients (36 eyes) 
who were treated with monthly injections of intravitreal bevacizumab for six months and then 
switched to monthly injections of ranibizumab for 12 months. Best-corrected visual acuity 
measurements (BCVA), contact lens biomicroscopy, optical coherence tomography (OCT), 
and fluorescein angiography were performed at the baseline examination and then monthly. 
Chi-square test was used for statistical analysis.
Results: Following bevacizumab treatment, retinal thickness decreased (P = 0.033) while 
BCVA improved (P = 0.040). Changing from bevacizumab to ranibizumab resulted in a transient 
decrease in BCVA (P = 0.045) and an increase in retinal thickness (P = 0.042). In addition, three 
eyes presented with a large subretinal hemorrhage. However, final retinal thickness was better 
than the initial thickness and the value following the bevacizumab course. No major ocular or 
systemic side effects were noted.
Conclusions: Ranibizumab was clinically effective in the long term but the change of treatment 
from bevacizumab to a half-size molecule with less half-life in the vitreous such as ranibizumab 
contributed to a transient “instability” in the eye which may have triggered the large subretinal 
hemorrhage. There is insufficient experience reported in the literature in switching from one 
agent to another. A prospective study with controls is necessary to determine whether it is safe 
to change from one medication to another.
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Introduction
Age-related macular degeneration (AMD) is the most common cause of visual loss in 
patients aged over 65 years.1 Neovascular AMD with the development of a choroidal neo-
vascularization (CNV) in the macular area accounts for 80% of the severe loss of visual 
acuity due to AMD.2,3 Ranibizumab (Lucentis®), an isotype monoclonal antibody fragment, 
is a recombinant humanized immunoglobulin (Ig1) designed for intraocular use which 
binds to and inhibits the biologic activity of human vascular endothelial growth factor 
(VEGF) A. The latter contributes to the development and/or progression of choroidal neo-
vascularization associated with neovascular (wet) AMD.4,5 Two-year results of the MARINA 
study and many other reports support the favorable results of ranibizumab.6–10
Bevacizumab (Avastin®) is a recombinant humanized full-length antibody that binds 
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has been offered as an off-label intravitreal application for 
the treatment of wet AMD.11–14
We report our experience with patients who were treated 
initially with intravitreal bevacizumab and then switched to 
ranibizumab for a follow-up period of 18 months.
Participants and methods
We retrospectively reviewed the records of 34 patients 
(36 eyes) who were treated initially with intravitreal 
bevacizumab 1.25 mg/0.05 mL for six months (six-monthly 
injections) and then switched to ranibizumab 0.5 mg for 
12 months (12 monthly injections) when the latter became 
commercially available in Greece. All patients were suffering 
from wet AMD and were older than 50 years. All types of 
neovascularization due to AMD were included in the study. 
Patients, who had photodynamic therapy with Visudyne® 
before starting the anti-VEGF treatment, were also included 
in the study. All patients had best-corrected visual acuity 
(BCVA) equal or better than 0.1. There were no eyes with 
evidence of other ocular disease than AMD during the 
18-month follow-up period.
Nonstandarized Snellen BCVA, slit-lamp examination, 
contact lens biomicroscopy, optical coherence tomography 
(OCT), and fluorescein angiography (FA) were performed at 
baseline examination and on a monthly basis. An intravitreal 
injection was performed every month. In all cases, when 
changing from bevacizumab to ranibizumab, the first 
ranibizumab injection was performed one month after the 
last bevacizumab injection in order to avoid a time interval 
delay in which the eye was not “covered” by any anti-VEGF 
treatment.
All injections were performed under standard sterile 
conditions and topical antibiotics were administered for 
four days. All patients were examined 3–4 days after the 
injection.
The study was approved by the hospital ethics committee. 
All patients signed an informed consent form after detailed 
explanation of the procedure.
The chi-square test was used for statistical analysis. 
A P-value less than 0.05 was considered to be statistically 
significant.
Results
Thirty-four patients (36 eyes) were treated during this 
18-month period. Mean age was 74.28 years. The youngest 
patient was aged 57 years and the oldest one was aged 
89 years. Of the 34 patients, 16 were men (47.05%) and 
18 were women (52.95%).
Initially, and before treatment, all 36 eyes had a mean 
retinal thickness of 417.81 µm and mean BCVA of 0.319. 
After the first injection of bevacizumab, the mean retinal 
thickness was decreased to 328.39 µm (P = 0.033), which was 
statistically significant. When the six-month bevacizumab 
course was completed, the mean retinal thickness had again 
decreased slightly to 316.19 µm. BCVA improved initially to 
0.477, and showed a slight further improvement (0.494) at the 
end of six months. Comparing the values before treatment and 
after the six-month bevacizumab course, the difference was 
statistically significant both in retinal thickness (P = 0.005) 
and in BCVA (P = 0.040). Changing from bevacizumab to 
ranibizumab resulted in a transient decrease in visual acuity 
(0.494 to 0.436; P = 0.045) and an increase in retinal thickness 
(316.19 to 336.08; P = 0.042), which are both statistically 
significant parameters. This decrease in visual acuity lasted 
for a period of two months. The first ranibizumab injection 
was performed one month after the last bevacizumab injec-
tion in order to avoid a time interval in which the eye was 
not “covered” by any anti-VEGF treatment. Ranibizumab 
treatment was continued for one year for all eyes.
Final statistically significant results showed that retinal 
thickness was decreased in comparison to the starting values 
(417.81 µm to 314.41 µm; P = 0.004). In comparison to 
the value after finishing bevacizumab treatment and before 
starting ranibizumab treatment and while showing some 
improvement, this result was not statistically significant 
(316.19 µm to 314.41 µm; P = 0.09) (Figure 1).
Although retinal thickness was significantly decreased 
at the end of the 18-month follow-up period, visual acuity 
did not improve as expected. In particular, final BCVA was 
0.398. While being better than the initial measurement 
(0.319), the final BCVA was worse in comparison to that 
after finishing bevacizumab treatment and before starting 
ranibizumab treatment (from 0.494 to 0.398; P = 0.019) 
(Figure 2).
Following each case in detail, during this 18-month 
period, we noted these results: Twenty-nine eyes (80.5%) 
showed immediate improvement both clinically (mean retinal 
thickness, 329.4) and in visual acuity (mean BCVA, 0.517) 
after the first bevacizumab injection while seven eyes (19.5%) 
remained stable (Mean retinal thickness, 324.0; mean BCVA, 
0.314). On completion of the six-month bevacizumab course, 
in seven eyes which were stable initially, five showed improve-
ments (mean retinal thickness, 255.0 µm; mean BCVA, 0.62) 
while two remained stable (mean retinal thickness, 254.0 µm; 
mean BCVA, 0.15). In changing from bevacizumab to ranibi-
zumab, there was a transient decrease in mean BCVA and Clinical Interventions in Aging 2009:4 459
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an increase in mean retinal thickness in OCT. In particular, 
one eye showed an increase in BCVA and a decrease in 
retinal thickness, 16 eyes showed deterioration in BCVA and 
increase in retinal thickness, and 19 eyes showed no change 
in BCVA with 17 of those having minor increase in retinal 
thickness while two noted a minor decrease. In addition, three 
patients (three eyes) from the deterioration group presented 
with a large subretinal hemorrhage within the first month 
of the first ranibizumab injection and although intravitreal 
injections of ranibizumab were continued, the hemorrhage 
expanded further, which resulted in a poor final BCVA. 
These patients were not on aspirin or other anticoagulant 
medication and did not have photodynamic therapy prior to 
the anti-VEGF treatment.
However, after one year of ranibizumab treatment, the 
final retinal thickness in OCT was improved from the initial 
measurement and was better than after the six-month course 
of bevacizumab. BCVA, although improved, did not follow 
these results. The latter can be explained because, in addition 
to the three eyes with large subretinal hemorrhage, 13 eyes 
with longstanding choroidal neovascular lesions were treated 
with multiple sessions of photodynamic therapy prior to the 
anti-VEGF treatment. This resulted in a final visual outcome 
that was worse than expected, although final retinal thickness 
did decrease.
Finally, no major ocular side effects such as endophthal-
mitis or retinal detachment were noted. Injection-site reac-
tion and floaters were reported in almost all cases but were 
innocuous and resolved without treatment. Subconjuctival 
hemorrhage was noted in only a few cases. In addition, there 
were no cases of systemic adverse events such as myocardial 
or cerebral infarction or treatment emerged hypertension and 
no patient died during the 18-month study.
Discussion
Ranibizumab (Lucentis®), an isotype monoclonal antibody 
fragment, is a recombinant humanized Ig1 designed for intra-
ocular use which binds to and inhibits the biologic activity 
of human VEGF A. Nearly 95% of patients with minimally 
classic or occultc choroidal neovascularization treated 
with intravitreal injections of ranibizumab lost fewer than 
15 letters compared with 62.2% of patients receiving placebo 
injections.6 Many other reports support these findings.7–10,15
Bevacizumab is a recombinant humanized full-length 
antibody that binds to all isoforms of VEGF, similar to ranibi-
zumab which has been offered as an off-label intravitreal 
application for the treatment of wet AMD.11–13,16,17
There is controversy over the use of ranibizumab and 
bevacizumab for treating AMD,18 which is the leading cause 
of blindness in people aged older than 65 years.1 Although 
both medications alone show very promising results and are 
now part of everyday practice, there has been no research 
documenting the results of change from one medication to 
another.
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Figure 2 Best-corrected visual acuity during the 18-month follow-up period.
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Figure 1 Retinal thickness in optical coherence tomography during the 18-month 
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Recently, Stepien and colleagues reported that there were 
no apparent differences in visual acuity or injection rate in 
switching from bevacizumab to ranibizumab therapy.19
Our study had a longer follow-up period and all patients 
had monthly injections. Using this protocol there was no 
time interval between changing anti-VEGF therapies and the 
eye was “covered” by anti-VEGF treatment during the entire 
follow-up period of 18 months. In comparison to Stepien 
and colleagues,19 this study showed that switching from 
bevacizumab to ranibizumab resulted in a transient decrease 
of visual acuity and an increase of retinal thickness causing 
a transient “instability” in the eye.
The PIER study showed that reducing monthly injections 
after the first three months resulted in a decrease of visual 
acuity.7 In our study, we injected bevacizumab monthly for 
six months followed by injections of ranibizumab monthly 
for one year. Thus, the decrease of visual acuity cannot be 
associated with any discontinuation of monthly anti-VEGF 
therapy.
Although a large subretinal hemorrhage may occur during 
anti-VEGF treatment without any obvious explanation,20 the 
above mentioned transient “instability” may have triggered 
the large subretinal hemorrhage. The possibility of subretinal 
hemorrhage following change from intravitreal bevacizumab 
to ranibizumab has been reported.21 In our three cases, 
patients were not on aspirin or other anticoagulant treatment 
and did not have photodynamic therapy prior to the anti-
VEGF treatment. According to the literature, complications 
such as retinal epithelial tears are known.22 In our cases, OCT 
covered the entire macular area, and did not show any signs 
of retinal tear, which could explain such a hemorrhage. It is 
known that the natural history and the visual outcome of a 
submacular hemorrhage in AMD are very poor.23 However, 
Stifter and colleagues24 reported that intravitreal bevaci-
zumab seems to be a promising therapeutic option in eyes 
with neovascular AMD and large submacular hemorrhages, 
with stabilization in BCVA and anatomic improvement. Our 
patients deteriorated further even although treatment was 
continued on a monthly basis.
In our study, eyes with longstanding choroidal neovas-
cular lesions were treated with multiple sessions of photo-
dynamic therapy prior the anti-VEGF treatment and had a 
less satisfactory visual outcome. It is known that photody-
namic therapy improves the prognosis of exudative AMD. 
However, its effectiveness differs among different subtypes 
of choroidal neovascularization. However, according to the 
literature, histopathological studies described retinal pigment 
epithelium alterations and occlusion of choriocappilaris 
lumina caused by damage to endothelial cells.25,26 In our 
study, after 18 months of follow up, both bevacizumab and 
ranibizumab proved effective in reducing retinal thickness 
and controlling the disease. However, in those cases treated 
with photodynamic therapy prior to the anti-VEGF treatment, 
the final visual outcome was less satisfactory. The latter can 
be associated with damage of retinal pigment epithelium 
and the choriocapillaris by the photodynamic therapy, the 
long-standing disease, or both.
This study has obvious limitations such as the small num-
ber of patients, the nonstandardized visual acuity measure-
ments and that it is retrospective. However, changing from 
one anti-VEGF agent to another is an aspect of anti-VEGF 
treatment which requires further investigation.
According to the literature, bevacizumab does not 
harm retinal function and is well tolerated by ganglion 
cells and photoreceptors.27–30 The molecular size of ranibi-
zumab and bevacizumab and their half-life in vitreous are 
different.28,29
Ranibizumab was clinically effective in the long term in 
reducing retinal thickness, but the change of treatment from a 
larger molecule such as bevacizumab to a half-size molecule 
with less half-life in vitreous such as ranibizumab may have 
contributed to this transient increase in retinal thickness 
and decrease in visual acuity. The latter created a transient 
“instability” in the eye which may have triggered the large 
subretinal hemorrhage. One possible solution to the change 
of medication would be to increase the dose of ranibizumab 
on the month of shifting. A prospective study with large 
series of patients and controls may be necessary in order to 
determine whether it is safe to change from one medication 
to another, or it is preferable to continue treatment with the 
same anti-VEGF agent for this disease.
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